A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really does help curb drinking ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

In the first clinical trial of its kind, people taking semaglutide drank less alcohol, adding to its promise of fighting addiction.

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.